Abstract
Peripheral T-cell lymphoma unspecified (PTCL/U) is a rare tumor characterized by poor treatment response and a dismal prognosis. We studied CD52 expression in 97 PTCL/U cases by immunohistochemistry on tissue-microarrays. Furthermore, CD52 gene expression was studied in 28 cases for which RNA was available. We found that CD52 is expressed in approximately 40% of PTCLs/U at the same level as in normal T-lymphocytes. Although other factors may play a role in the in vivo response to alemtuzumab, an anti-CD52 monoclonal antibody, the estimation of CD52 expression may provide a rationale for the selection of patients with a higher probability of treatment response.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alemtuzumab
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / immunology
-
Antibodies, Neoplasm / therapeutic use
-
Antigens, CD / biosynthesis*
-
Antigens, CD / genetics
-
Antigens, CD / immunology
-
Antigens, Neoplasm / biosynthesis*
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / immunology
-
CD52 Antigen
-
Gene Expression Profiling
-
Glycoproteins / biosynthesis*
-
Glycoproteins / genetics
-
Glycoproteins / immunology
-
Humans
-
Lymphoma, T-Cell, Peripheral / metabolism*
-
Lymphoma, T-Cell, Peripheral / pathology
-
Oligonucleotide Array Sequence Analysis
-
Paraffin Embedding
-
RNA, Messenger / biosynthesis
-
RNA, Messenger / genetics
-
RNA, Neoplasm / biosynthesis
-
RNA, Neoplasm / genetics
-
T-Lymphocytes / metabolism*
-
T-Lymphocytes / pathology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antigens, CD
-
Antigens, Neoplasm
-
CD52 Antigen
-
CD52 protein, human
-
Glycoproteins
-
RNA, Messenger
-
RNA, Neoplasm
-
Alemtuzumab